- Home
- / Millendo Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Millendo Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.1
2021-07-01
Market Capitalization
$20.2 M
2021-07-01
Revenue
$295 K
FY, 2017
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 277.0K | 653.0K | 295.0K | ||||||||
| Cost of goods sold | 2.2M | 5.4M | 790.0K | ||||||||
| Gross profit | (2.0M) | (4.7M) | (495.0K) | ||||||||
| Gross profit margin, % | -711.9% | -727.1% | -167.8% | ||||||||
| General and administrative expense | 7.2M | 13.3M | 26.1M | 51.6M | 49.2M | 27.7M | 8.7M | 17.6M | 15.6M | 9.8M | 12.1M |
| Operating expense total | 13.5M | 29.1M | 47.9M | 70.0M | 76.3M | 50.1M | 23.1M | 45.4M | 36.0M | 34.6M | |
| EBIT | (13.5M) | (29.1M) | (47.9M) | (72.0M) | (81.0M) | (50.6M) | (27.0M) | (34.6M) | |||
| EBIT margin, % | -25992.4% | -12406.1% | -17154.6% | ||||||||
| Investment income | (1.6M) | 436.0K | 659.0K | 752.0K | |||||||
| Interest income | 19.0K | 90.0K | 126.0K | ||||||||
| Interest expense | 134.0K | ||||||||||
| Pre tax profit | (73.1M) | (82.1M) | (50.9M) | ||||||||
| Income tax expense | 75.0K | 201.0K | 67.0K | ||||||||
| Net Income | (13.5M) | (29.0M) | (49.5M) | (73.2M) | (82.3M) | (51.0M) | (27.2M) | (44.6M) | (36.4M) | (28.3M) | (35.7M) |
| EPS | (3.1) |